North Shore University Hospital Research Corporation

North Shore-Long Island Jewish Research Institute

Long Island Jewish Medical Center

North Shore-Long Island Jewish Health System

Angion Biomedica Corporation

Itzhak D Goldberg

Eliot M Rosen

Sivaram Pillarisetti

An-Hu Li

Dong Sung Lim

Dawoon Jung

Prakash Narayan

Quaisar Ali

Swarnalatha Paka

Gary H Weiss

Dibyendu Dana

Satishkumar Gadhiya

The present invention provides compounds having formula (I): and pharmaceutically acceptable salts thereof, wherein Cy1, Cy2, Cy3, R, R, R, R, Aand Aare as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which inhibiting ROCK1, ROCK2, or ROCK1/2 has a therapeutically useful role.

Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors

The invention is directed to small organic molecules having the ability to mimic or agonize hepatocyte growth factor/scatter factor (HGF/SF) activity, or inhibit or antagonize HGF/SF activity, the former useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction. Inhibition of cellular growth or proliferation is beneficial in the treatment, for example, of inflammatory diseases such as inflammatory joint and skin diseases, and dysproliferative diseases such as cancer.

Small-molecule modulators of hepatocyte growth factor / scatter factor activities

The invention is directed to pharmaceutical compositions containing small organic molecules having the ability to mimic or agonize hepatocyte growth factor/scatter factor (HGF/SF) activity, useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction.

Compositions and agents for modulating cellular proliferation and angiogenesis

Small-molecule modulators of hepatocyte growth factor/scatter factor activities

This invention relates to a method of enhancing wound healing and to a method of enhancing organ transplantation utilizing scatter factor, either alone or in combination with a growth factor.

Use of scatter factor to enhance angiogenesis

Method for reducing angiogenesis by administration of a scatter factor inhibitor

The present invention provides a novel method of inducing proliferation and migration of endothelial cells in a subject comprising administering an amount of scatter factor effective to induce the proliferation and migration of endothelial cells in the subject.

Method for inducing the proliferation and migration of endothelial cells

The present invention provides a novel method of determining the presence of angiogenesis in a subject comprising detecting the presence of scatter factor in the subject.

Method for determining angiogenesis using scatter factor

The present invention provides a novel method of inhibiting angiogenesis in a subject by blocking the ability of endogenous scatter factor to promote angiogenesis in the subject. The endogenous scatter factor may be blocked by using an inhibitor to scatter factor, such as an antibody.

Inhibition of scatter factor for blocking angiogenesis

The present invention provides a novel method of enhancing transplanted tissue in a subject comprising administering an amount of scatter factor effective to promote angiogenesis and enhance tissue transplantation in the subject.

Method for enhancing transplanted tissue using scatter factor

This invention relates to a method of promoting angiogenesis utilizing scatter factor, either alone or in combination with a growth factor.

This invention relates to a method of enhancing wound healing utilizing scatter factor, either alone or in combination with a growth factor.

This invention relates to a method of diagnosing and screening for transitional cell carcinoma of the bladder. Urine from an individual suspected of having transitional cell carcinoma of the bladder is analyzed for the presence of an increased level of scatter factor, an increased level of scatter factor indicating that said individual has bladder cancer. This invention further relates to a method of monitoring bladder cancer activity by measuring the level of scatter factor in urine, and to a method of determining the prognosis of an individual having bladder cancer by measuring the level of scatter factor in tumor extract from the individual.

Growing community of inventors

Englewood, NJ, United States of America

Itzhak D Goldberg